Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2017

View Archived Issues

Otsuka Pharmaceutical recaps highlights of first quarter 2017

LV.CD11b.IDS for the treatment of neurocognitive impairments in an MPS II mouse model

FDA places CTP-543 phase IIa study on hold

Shire initiates phase I study of SHP-639 in intraocular hypertension and primary open-angle glaucoma

Promising clinical results seen with AAV2-AADC for AADC deficiency

rAAV9-CBA-hNAGLUop optimized gene delivery for treating MPS IIIB

FDA approves Kalydeco to treat cystic fibrosis in patients with certain residual function mutations

Omeros provides update on phase II study of OMS-721

Bristol-Myers Squibb patents casein kinase II inhibitors

Vifor presents ferroportin inhibitors

Aurinia initiates phase III study of voclosporin for lupus nephritis

Quanterix launches Simoa Neurology 4-Plex A assay to study traumatic brain injury severity

Heptares Therapeutics identifies calcitonin gene-related peptides receptor antagonists

FDA grants breakthrough therapy designation to GMI-1271 for relapsed or refractory AML

Merck & Co. discovers coagulation factor XIa and kallikrein inhibitors

Sun Pharma Advanced Research discloses estrogen receptor antagonists

Aduro Biotech expands clinical collaboration with Merck & Co.

Nanobiotix reports clinical data on potential role of NBTXR-3 in immuno-oncology

Teva nominates preclinical candidate CGRP antagonist for advancement to treat migraine

NC16A IgG4 may be a serum diagnostic marker of eosinophilic esophagitis

Specialised Therapeutics and PharmaMar enter lurbinectedin licensing agreement

miR-155 found as a predictor of methotrexate nonresponse in rheumatoid arthritis patients

Evaluation of novel anti-MUC1 (CAR)-modified T cells for the treatment of breast cancer